Pulike Biological Engineering, Inc.

Shanghai Stock Exchange 603566.SS

Pulike Biological Engineering, Inc. Current Liabilities for the year ending December 31, 2023: USD 71.56 M

Pulike Biological Engineering, Inc. Current Liabilities is USD 71.56 M for the year ending December 31, 2023, a -10.92% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Pulike Biological Engineering, Inc. Current Liabilities for the year ending December 31, 2022 was USD 80.32 M, a 47.68% change year over year.
Pulike Biological Engineering, Inc. Current Liabilities for the year ending December 31, 2021 was USD 54.39 M, a 22.63% change year over year.
Pulike Biological Engineering, Inc. Current Liabilities for the year ending December 31, 2020 was USD 44.35 M, a 44.29% change year over year.
Pulike Biological Engineering, Inc. Current Liabilities for the year ending December 31, 2019 was USD 30.74 M, a -11.03% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Shanghai Stock Exchange: 603566.SS

Pulike Biological Engineering, Inc.

CEO	Mr. Wei Hu
IPO Date	May 18, 2015
Location	China
Headquarters	No.15 Zhenghe Road
Employees	1,679
Sector	Healthcare
Industries Biotechnology Pet Food Pharmaceuticals Vaccines

Description

Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company is headquartered in Luoyang, China.

Key trends

Past 5 years